Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-014731
Filing Date
2022-08-04
Accepted
2022-08-04 16:04:02
Documents
73
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ntla-20220630.htm   iXBRL 10-Q 3331780
2 EX-10.1 ntla-ex10_1.htm EX-10.1 35002
3 EX-10.2 ntla-ex10_2.htm EX-10.2 66134
4 EX-31.1 ntla-ex31_1.htm EX-31.1 16838
5 EX-31.2 ntla-ex31_2.htm EX-31.2 16855
6 EX-32.1 ntla-ex32_1.htm EX-32.1 10712
  Complete submission text file 0000950170-22-014731.txt   12245168

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ntla-20220630_lab.xml EX-101.LAB 477929
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ntla-20220630_pre.xml EX-101.PRE 369216
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ntla-20220630_def.xml EX-101.DEF 234637
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ntla-20220630.xsd EX-101.SCH 58143
11 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ntla-20220630_cal.xml EX-101.CAL 41818
67 EXTRACTED XBRL INSTANCE DOCUMENT ntla-20220630_htm.xml XML 2792977
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 221136423
SIC: 2835 In Vitro & In Vivo Diagnostic Substances